Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Merck & Co. Inc. stock reached a 52-week high, closing at $122.69. This milestone highlights a significant upward trend for the pharmaceutical giant, marking a notable recovery and growth over the ...

Merck (MRK) is back in focus after Health Canada cleared KEYTRUDA SC, a subcutaneous version of its flagship cancer therapy, alongside a new AI-focused drug discovery partnership with Mayo Clinic that ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Merck & Co. is no longer a deep-value patent cliff trade but a fairly valued defensive compounder. Read why I have downgraded ...

These two tried-and-tested healthcare giants have compelling portfolios and pipelines. Pfizer is moving on from the pandemic era, and a stream of acquisitions has bolstered its pipeline. Merck has one ...

Merck KGaA stock: what recent performance says about investor sentiment Merck KGaA (XTRA:MRK) has seen a mix of outcomes for shareholders, with a 3.3% year to date return, a 5.1% decline over the past ...

Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total ...